Follow-up of focal therapy treatment: Caveats to current recommendations

Acknowledgments

We thank the Cabrini Foundation for financial support.

Statement of ethics

Not applicable.

Conflict of interest statement

The authors declare no conflicts of interest.

Funding source

This work was supported by the Cabrini Foundation.

Author contributions

KYL: writing - original draft preparation;

JS, WR, MF: Writing - review and editing;

All authors have read and agreed to the published version of the manuscript.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

[1] Ong S, Chen K, Grummet J, et al. Guidelines of guidelines: Focal therapy for prostate cancer, is it time for consensus? BJU Int 2023; 131(1):20-31.

[2] Sanchez-Salas R, Desai M (eds) (2015) Guided Therapies for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Societé Internationale d'Urologie (SIU). ISBN: 978-0-9877465-9-7. Available at: https://www.siu-urology.org/themes/web/assets/files/ICUD/pdf/image-guided_therapies.pdf Published by the Société Internationale d’Urologie (SIU). Location Montreal, Quebec, Canada. Accessed July 19, 2025.

[3] Huber PM, Afzal N, Arya M, et al. Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. J Urol 2020; 203(4):734-742.

[4] Koopman A, Jenniskens SFM, Futterer JJ. Magnetic resonance imaging assessment after therapy in prostate cancer. Top Magn Reson Imaging 2020; 29(1):47-58.

[5] Ahn H, Hwang SI, Kim TM, et al. Diagnostic value of multiparametric MRI in detecting residual or recurrent prostate cancer after high-intensity focused ultrasound. Prostate Cancer Prostatic Dis 2023; 26(2):360-366.

[6] Geboers B, Gondoputro W, Thompson JE, et al. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following irreversible electroporation—A multicenter validation study. Eur Urol Focus 2022; 8(6):1591-1598.

[7] Sonni I, Eiber M, Fendler WP, et al. Impact of ⁶⁸Ga- PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: A prospective single-center study. J Nucl Med 2020; 61(8):1153-1160.

[8] Burger IA, Muller J, Donati OF, et al. ⁶⁸Ga-PSMA-11 PET/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU. J Nucl Med 2019; 60(8):1118-1123.

[9] Apfelbeck M, Chaloupka M, Schlenker B, Stief CG, Clevert DA. Follow-up after focal therapy of the prostate with high intensity focused ultrasound (HIFU) using contrast enhanced ultrasound (CEUS) in combination with MRI image fusion. Clin Hemorheol Microcirc 2019; 73(1):135-143.

[10] Matulevičius A, Žukauskaitė K, Gineikaitė R, et al. Combination of DNA methylation biomarkers with multiparametric magnetic resonance and ultrasound imaging fusion biopsy to detect the local spread of prostate cancer. Prostate 2023; 83(16):1572-1583.